Skip to content
etf.net

THNR

GradeCNew York Stock Exchange Arca

Amplify Weight Loss Drug & Treatment ETF

Themes · Amplify · Inception 2024-05-21

$25.89−0.44 (−1.68%)

As of Sep 23, 2026, 2:20 PM EDT

History starts May 21, 2024.
Intraday session: down, 57 prints from 26.34 to 25.89. Range 25.77 to 26.29. Use the arrow keys to read each point.$25.80$26.00$26.2010 AM12 PM2 PM4 PM
Expense ratio
0.59%
Fund size
$6M
1Y return
+12.4%
Yield · Last 12 months
1.57%
Holdings
20
Volume · 30D
0M sh
NAV per share
$26.23
52W range
low $22.63high $27.94

The ETF.net THNR Grade

C

43/ 100

Rank 8 of 9 in Pharma & Therapeutics⁠

Confidence High

Six-pillar profile for THNR. Scores out of 100: Cost 41, Risk 34, Mission 67, Tradability 14, Holdings 66, Durability 18. Strongest: Mission (67). Weakest: Tradability (14). Leans toward Mission and Holdings.
F< 25
D≥ 25
C≥ 40
B≥ 55
A≥ 70

Score 43 of 100 sits in the C band. Bands: A ≥ 70, B ≥ 55, C ≥ 40, D ≥ 25, F < 25; the scale skips E.

  • Cost

    What you pay to own it — the expense ratio plus trading frictions, ranked within its category.
    CScore 41
    Category rank7/9 · bottom quartile

  • Mission

    How faithfully it does the job it claims — tracking its mandate or index with minimal slippage.
    BScore 67
    Category rank5/6 · bottom quartile

  • Risk

    How violently it can move — volatility, drawdown depth, and downside capture versus its category.
    DScore 34
    Category rank7/9 · bottom quartile

  • Tradability

    How cheaply and easily you can get in and out — liquidity, spread, and premium/discount stability.
    FScore 14
    Category rank9/9 · bottom quartile

  • Holdings

    What it actually owns — the quality, breadth, and concentration of the underlying portfolio.
    BScore 66
    Category rank4/9 · top 44%

  • Durability

    Whether it will still be here — the fund’s assets, age, flows, and issuer staying power.
    FScore 18
    Category rank9/9 · bottom quartile

Graded as of Sep 22, 2026

Our read on THNR

ETF.net Research

CThe GLP-1 trade in one ticker. THNR follows a global index of weight-loss drug developers plus the telehealth and treatment companies the index counts as economic beneficiaries, not just the obvious pharma giants.

Stated mandate

The fund provides access to global companies involved in weight-loss drug development or expected to benefit economically from increased use of these treatments, including drug manufacturers and telehealth providers.

Why people hold it

  1. 01Casts wider than the drugmakers: the mandate covers telehealth providers and other firms tied to rising use of weight-loss treatments.amplifyetfs.com
  2. 02Rules-based, not a hunch. It tracks VettaFi's Weight Loss Drug & Treatment Index (THINR), so the lineup changes by published methodology.
  3. 03Global by design, so European drugmakers count as much as US ones. Launched in 2024, as GLP-1 treatments moved from niche to headline.

Worth knowing

  1. 01The 0.59% expense ratio runs a touch above what global thematic funds typically charge.
  2. 02A small fund that trades lightly, so spreads can be wider than on big index funds. Limit orders are the usual tool here.
  3. 03One storyline, one drug class. Concentrated by construction, and distributions land annually or semiannually rather than as steady income.

THNR Holdings

As of Sep 20, 2026, 5:09 AM
Asset class
Stocks
Holdings
20
Top-10 weight
61%
Largest holding
LLY10.0%

Sectors

Geography

The fund’s holdings, weight-ordered — page 1 of 2.
#TickerCompanyWeight %SharesMarket valueIn ETFs
001LLYEli Lilly & Co9.95%503$580K569
002NVONovo Nordisk A/S9.52%12,835$555K35
003AZNAstraZeneca PLC5.38%1,888$314K68
004ROP.SWRoche Holding AG5.26%708$307K196
005AMGNAmgen Inc5.22%788$304K470
006GILDGilead Sciences Inc5.21%2,024$304K482
007ABBVAbbVie Inc5.21%1,149$303K511
0081801.HKInnovent Biologics Inc5.18%24,500$302K88
009PFEPfizer Inc5.17%10,896$301K374
0104519.TChugai Pharmaceutical Co Ltd5.15%7,000$300K136
011REGNRegeneron Pharmaceuticals Inc5.12%380$298K401
0121093.HKCSPC Pharmaceutical Group Ltd5.12%262,000$298K81
013MRKMerck & Co Inc5.10%2,025$297K506
014VKTXViking Therapeutics Inc4.54%9,118$264K94
015ZEAL.COZealand Pharma A/S4.11%5,542$240K56

Showing 1–15 of 21 holdings

THNR Performance

Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.

THNR$11,240
SPY tracks large US stocks. It provides market context, rather than representing this fund’s strategy, asset class or investment benchmark.$11,723
Sep 22, 2025 to Sep 22, 2026. THNR $11,240. SPY $11,723. Use the arrow keys to read each point.$9,339$10,732$12,124Sep 2025Mar 2026Sep 2026

Sep 22, 2025 – Sep 22, 2026

Returns run to the Sep 22, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.

Trailing total return for THNR. Periods over one year show the average yearly return.
PeriodTHNR
Year to date+4.2%
1 month−4.5%
3 months+7.6%
1 year+12.4%
3 yearsFund is under 3 years old—per year
5 yearsFund is under 5 years old—per year
10 yearsFund is under 10 years old—per year

As of the close, with distributions reinvested.

Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.

Annual total returns for THNR
YearReturn barTHNR
2026 YTD+4.2%
2025+13.7%
2024−10.4%

Since listing, May 21, 2024

THNR in the news

ETF.net Research hasn’t filed on THNR yet — coverage lands here as it’s written.

THNR Dividends

Adds up every distribution paid per share over the last 12 months, divided by the last completed close. Distributions are counted by ex-date. Data through Sep 22, 2026.
1.57%Last 12 months
Payout per share
$0.41Last 12 months
Last payment
$0.41 per share
Paid on
Shares bought on or after this date do not qualify for this distribution.
Frequency
Irregular

Distribution history

2024–2026

One bar per payment. 2 payments from 2024 to 2026 YTD. Dec 30, 2024 $0.22; Dec 30, 2025 $0.41. Use the arrow keys to read each point.202420252026YTD
Ex-datePay dateAmount per share
Dec 30, 2025Dec 31, 2025$0.41
Dec 30, 2024Dec 31, 2024$0.22

THNR Risk

How much the fund’s monthly returns vary, scaled to a year.
14.9%
Annualised · 27 months to Aug 2026
How it’s calculated: standard deviation

The sample standard deviation of monthly total returns, multiplied by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.

Return above 3-month US Treasury bills per unit of volatility.
0.02
vs 3-month T-bills · 27 months to Aug 2026
How it’s calculated: Sharpe ratio

Subtract each month’s Treasury-bill return from the fund’s monthly total return.

Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.

The largest fall from a peak to the low that followed.
−32.5%
28 months · trough Apr 2025
How it’s calculated: maximum drawdown

The largest percentage decline from an earlier peak, using total returns with reinvested distributions.

Uses up to five years through the last close, with at least 12 months required.

How strongly the fund’s returns move with its asset-class index.
0.40
vs its asset-class index
How it’s calculated: beta

The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.

THNR Cost

Expense ratio0.59%
  • The middle half of Pharma & Therapeutics funds
  • Median 0.58%

5 of the 9 Pharma & Therapeutics funds charge less.

THNR costs $59.00 a year on $10,000. The median Pharma & Therapeutics fund costs $58.00.